Cargando…
Lifestyle Intervention in Chronic Ischaemic Heart Disease and Type 2 Diabetes (the LeIKD study): study protocol of a prospective, multicentre, randomised, controlled trial
INTRODUCTION: Guidelines recommend lifestyle intervention in chronic ischaemic heart disease (CIHD) and type 2 diabetes mellitus (T2DM). However, evidence from randomised controlled trials is scarce in patients with combined entities. METHODS AND ANALYSIS: The Lifestyle Intervention in Chronic Ischa...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871688/ https://www.ncbi.nlm.nih.gov/pubmed/33558354 http://dx.doi.org/10.1136/bmjopen-2020-042818 |
_version_ | 1783649058948120576 |
---|---|
author | von Korn, Pia Sydow, Hanna Neubauer, Sarah Duvinage, André Mocek, Anja Dinges, Sophia Hackenberg, Bjoern Weichenberger, Mario Schoenfeld, Julia Amelung, Volker Mueller, Stephan Halle, Martin |
author_facet | von Korn, Pia Sydow, Hanna Neubauer, Sarah Duvinage, André Mocek, Anja Dinges, Sophia Hackenberg, Bjoern Weichenberger, Mario Schoenfeld, Julia Amelung, Volker Mueller, Stephan Halle, Martin |
author_sort | von Korn, Pia |
collection | PubMed |
description | INTRODUCTION: Guidelines recommend lifestyle intervention in chronic ischaemic heart disease (CIHD) and type 2 diabetes mellitus (T2DM). However, evidence from randomised controlled trials is scarce in patients with combined entities. METHODS AND ANALYSIS: The Lifestyle Intervention in Chronic Ischaemic Heart Disease and Type 2 Diabetes (LeIKD) trial is a prospective, multicentre study that will randomise (1:1) patients with CIHD (ICD-10: I20-I25) and T2DM (ICD-10: E11) from one health insurance company into a lifestyle intervention (LS) or usual care (UC). Active LS consists of an individual combined exercise programme of strength and endurance training and nutritional counselling with regular feedback for 6 months. Intervention is supported by telemedicine. Follow-up without individualised feedback will continue for 6 months. The study aims to investigate whether an individualised telemedical supported LS intervention is superior to UC in improving cardiovascular risk factors, physical activity, quality of life, health literacy, major cardiovascular events and health economics in patients with both CIHD and T2DM. Primary endpoint is the change in HbA(1c) from baseline to 6 months. ETHICS AND DISSEMINATION: The study has been approved by the ethics committee of the Technical University of Munich (registration number: 144/18-S) and at each study site. The study will be conducted according to the World Medical Association Declaration of Helsinki, and results will be published in articles and reports. It is funded by the Federal Joint Committee (www.innovationsfonds.g-ba.de), reference number 01NVF17015, which has no impact on data collection, analysis or interpretation. Dissemination is independent of the funding source. TRIAL REGISTRATION NUMBER: Clinical trials.gov identifier: NCT03835923. German registry for clinical studies (DRKS): DRKS00015140. |
format | Online Article Text |
id | pubmed-7871688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-78716882021-02-18 Lifestyle Intervention in Chronic Ischaemic Heart Disease and Type 2 Diabetes (the LeIKD study): study protocol of a prospective, multicentre, randomised, controlled trial von Korn, Pia Sydow, Hanna Neubauer, Sarah Duvinage, André Mocek, Anja Dinges, Sophia Hackenberg, Bjoern Weichenberger, Mario Schoenfeld, Julia Amelung, Volker Mueller, Stephan Halle, Martin BMJ Open Sports and Exercise Medicine INTRODUCTION: Guidelines recommend lifestyle intervention in chronic ischaemic heart disease (CIHD) and type 2 diabetes mellitus (T2DM). However, evidence from randomised controlled trials is scarce in patients with combined entities. METHODS AND ANALYSIS: The Lifestyle Intervention in Chronic Ischaemic Heart Disease and Type 2 Diabetes (LeIKD) trial is a prospective, multicentre study that will randomise (1:1) patients with CIHD (ICD-10: I20-I25) and T2DM (ICD-10: E11) from one health insurance company into a lifestyle intervention (LS) or usual care (UC). Active LS consists of an individual combined exercise programme of strength and endurance training and nutritional counselling with regular feedback for 6 months. Intervention is supported by telemedicine. Follow-up without individualised feedback will continue for 6 months. The study aims to investigate whether an individualised telemedical supported LS intervention is superior to UC in improving cardiovascular risk factors, physical activity, quality of life, health literacy, major cardiovascular events and health economics in patients with both CIHD and T2DM. Primary endpoint is the change in HbA(1c) from baseline to 6 months. ETHICS AND DISSEMINATION: The study has been approved by the ethics committee of the Technical University of Munich (registration number: 144/18-S) and at each study site. The study will be conducted according to the World Medical Association Declaration of Helsinki, and results will be published in articles and reports. It is funded by the Federal Joint Committee (www.innovationsfonds.g-ba.de), reference number 01NVF17015, which has no impact on data collection, analysis or interpretation. Dissemination is independent of the funding source. TRIAL REGISTRATION NUMBER: Clinical trials.gov identifier: NCT03835923. German registry for clinical studies (DRKS): DRKS00015140. BMJ Publishing Group 2021-02-08 /pmc/articles/PMC7871688/ /pubmed/33558354 http://dx.doi.org/10.1136/bmjopen-2020-042818 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Sports and Exercise Medicine von Korn, Pia Sydow, Hanna Neubauer, Sarah Duvinage, André Mocek, Anja Dinges, Sophia Hackenberg, Bjoern Weichenberger, Mario Schoenfeld, Julia Amelung, Volker Mueller, Stephan Halle, Martin Lifestyle Intervention in Chronic Ischaemic Heart Disease and Type 2 Diabetes (the LeIKD study): study protocol of a prospective, multicentre, randomised, controlled trial |
title | Lifestyle Intervention in Chronic Ischaemic Heart Disease and Type 2 Diabetes (the LeIKD study): study protocol of a prospective, multicentre, randomised, controlled trial |
title_full | Lifestyle Intervention in Chronic Ischaemic Heart Disease and Type 2 Diabetes (the LeIKD study): study protocol of a prospective, multicentre, randomised, controlled trial |
title_fullStr | Lifestyle Intervention in Chronic Ischaemic Heart Disease and Type 2 Diabetes (the LeIKD study): study protocol of a prospective, multicentre, randomised, controlled trial |
title_full_unstemmed | Lifestyle Intervention in Chronic Ischaemic Heart Disease and Type 2 Diabetes (the LeIKD study): study protocol of a prospective, multicentre, randomised, controlled trial |
title_short | Lifestyle Intervention in Chronic Ischaemic Heart Disease and Type 2 Diabetes (the LeIKD study): study protocol of a prospective, multicentre, randomised, controlled trial |
title_sort | lifestyle intervention in chronic ischaemic heart disease and type 2 diabetes (the leikd study): study protocol of a prospective, multicentre, randomised, controlled trial |
topic | Sports and Exercise Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871688/ https://www.ncbi.nlm.nih.gov/pubmed/33558354 http://dx.doi.org/10.1136/bmjopen-2020-042818 |
work_keys_str_mv | AT vonkornpia lifestyleinterventioninchronicischaemicheartdiseaseandtype2diabetestheleikdstudystudyprotocolofaprospectivemulticentrerandomisedcontrolledtrial AT sydowhanna lifestyleinterventioninchronicischaemicheartdiseaseandtype2diabetestheleikdstudystudyprotocolofaprospectivemulticentrerandomisedcontrolledtrial AT neubauersarah lifestyleinterventioninchronicischaemicheartdiseaseandtype2diabetestheleikdstudystudyprotocolofaprospectivemulticentrerandomisedcontrolledtrial AT duvinageandre lifestyleinterventioninchronicischaemicheartdiseaseandtype2diabetestheleikdstudystudyprotocolofaprospectivemulticentrerandomisedcontrolledtrial AT mocekanja lifestyleinterventioninchronicischaemicheartdiseaseandtype2diabetestheleikdstudystudyprotocolofaprospectivemulticentrerandomisedcontrolledtrial AT dingessophia lifestyleinterventioninchronicischaemicheartdiseaseandtype2diabetestheleikdstudystudyprotocolofaprospectivemulticentrerandomisedcontrolledtrial AT hackenbergbjoern lifestyleinterventioninchronicischaemicheartdiseaseandtype2diabetestheleikdstudystudyprotocolofaprospectivemulticentrerandomisedcontrolledtrial AT weichenbergermario lifestyleinterventioninchronicischaemicheartdiseaseandtype2diabetestheleikdstudystudyprotocolofaprospectivemulticentrerandomisedcontrolledtrial AT schoenfeldjulia lifestyleinterventioninchronicischaemicheartdiseaseandtype2diabetestheleikdstudystudyprotocolofaprospectivemulticentrerandomisedcontrolledtrial AT amelungvolker lifestyleinterventioninchronicischaemicheartdiseaseandtype2diabetestheleikdstudystudyprotocolofaprospectivemulticentrerandomisedcontrolledtrial AT muellerstephan lifestyleinterventioninchronicischaemicheartdiseaseandtype2diabetestheleikdstudystudyprotocolofaprospectivemulticentrerandomisedcontrolledtrial AT hallemartin lifestyleinterventioninchronicischaemicheartdiseaseandtype2diabetestheleikdstudystudyprotocolofaprospectivemulticentrerandomisedcontrolledtrial |